EP Wealth Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.74M Buy
40,819
+16,062
+65% +$872K 0.01% 611
2026
Q1
$1.55M Sell
24,757
-3,982
-14% -$319K 0.01% 539
2025
Q4
$2.74M Buy
+28,739
New +$2.82M 0.01% 378
2025
Q2
$3.78M Sell
35,146
-457
-1% -$46.2K 0.02% 303
2025
Q1
$3.59M Buy
35,603
+16,149
+83% +$1.63M 0.03% 265
2024
Q4
$1.74M Buy
19,454
+3,513
+22% +$309K 0.01% 379
2024
Q3
$1.34M Buy
15,941
+2,875
+22% +$227K 0.01% 434
2024
Q2
$1.01M Buy
13,066
+514
+4% +$37.6K 0.01% 389
2024
Q1
$860K Buy
12,552
+497
+4% +$32K 0.01% 403
2023
Q4
$697K Buy
12,055
+3,804
+46% +$203K 0.01% 432
2023
Q3
$436K Sell
8,251
-10,088
-55% -$529K 0.01% 479
2023
Q2
$470K Hold
18,339
0.01% 477
2023
Q1
$1.4M Buy
18,339
+10,140
+124% +$478K 0.02% 263
2022
Q4
$379K Buy
+8,199
New +$355K 0.01% 425
2022
Q3
Sell
-5,474
Closed -$204K 373
2022
Q2
$204K Buy
+5,474
New +$223K ﹤0.01% 567

Other funds holding BSX

EP Wealth Advisors's BSX Position: Q2 2026 in Review

EP Wealth Advisors increased its Boston Scientific (BSX) stake by 65% in Q2 2026, buying an estimated $872K and bringing the position to 40,819 shares worth $1.74M. The position accounts for 0.01% of the portfolio, ranked #611.

EP Wealth Advisors first reported a position in BSX in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.78M in Q2 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • EP Wealth Advisors held 40,819 shares of Boston Scientific worth $1.74M as of Q2 2026.
  • EP Wealth Advisors bought 16,062 Boston Scientific shares in Q2 2026, an estimated $872K.
  • Boston Scientific made up 0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #611 holding.
  • EP Wealth Advisors first reported a position in Boston Scientific in Q2 2022 and has held it in 15 quarters since.
  • EP Wealth Advisors's Boston Scientific position peaked at $3.78M in Q2 2025.
  • 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.